Cagrilintide + Semaglutide (CagriSema)

Regulatory Notice - Semaglutide: Semaglutide (Ozempic® / Wegovy® / Rybelsus®) is an FDA-approved prescription drug. RCDbio does not supply semaglutide as a pharmaceutical product. This research kit is a laboratory reagent only and does not represent a clinical alternative or therapeutic substitute.

Three Research Kit Formats: CS5 - 2.5mg cagrilintide + 2.5mg semaglutide (5mg/vial, single vial) · CS10 - 5mg + 5mg per vial, 10-vial kit (100mg total) · CS20 - 10mg + 10mg per vial, 10-vial kit (200mg total). Identical compound, 1:1 ratio, and mechanism across all three. Kit format selected based on research programme scale and duration.

What is Cagrilintide + Semaglutide (CagriSema)?

Cagrilintide + Semaglutide - marketed under the investigational name CagriSema - is a dual-peptide research formulation pairing two pharmacologically distinct synthetic peptides that operate on entirely separate receptor systems within the neuroendocrine appetite regulation axis. Cagrilintide (AM833, NN0174-0833, CAS 1415456-99-3) is a 37-amino acid lipidated, disulfide-bridged amylin analog classified as a DACRA (Dual Amylin and Calcitonin Receptor Agonist) - engineered to engage all four amylin and calcitonin receptor subtypes (AMY1R, AMY2R, AMY3R, and CTR) with a plasma half-life of approximately 159–195 hours. Semaglutide (NN9535, CAS 910463–68–2) is a 31-residue fatty-acid-modified GLP-1 receptor agonist with an approximately 160-hour half-life. The defining feature of this combination in published investigational research is mechanistic non-overlap: the two peptides target structurally unrelated receptor families, activate distinct intracellular signalling cascades, and project through different neural circuits in the brainstem - making their co-administration a research tool for investigating convergent appetite pathway pharmacology rather than redundant receptor agonism.

This compound is not approved by the U.S. FDA for human or veterinary use in any form. It is not a dietary supplement or consumer product. Availability is restricted to qualified researchers and licensed laboratory institutions. Note: semaglutide is an FDA-approved prescription drug. This kit is a research reagent only. IRB guidance is required for clinical research. IACUC compliance is required for preclinical animal research.

Chemical Properties

Shared Properties - All Three SKUs

SKU Format Comparison

How Does Cagrilintide + Semaglutide Work?

Cagrilintide → Amylin/Calcitonin Receptor Family (DACRA Pharmacology): Structurally, cagrilintide incorporates a C16 fatty-diacid side chain at an optimized acylation site on the 37-AA peptide backbone. This modification drives reversible albumin binding in plasma, extending the half-life to approximately 159–195 hours. At the receptor interface, cryo-EM structural analysis (Cao et al. 2025, Nat Commun) resolved a 'bypass' binding geometry distinct from those of earlier amylin analogs: the F23Cagri residue inserts directly into the receptor transmembrane bundle rather than engaging via N-terminal interactions; an intramolecular E14–R17 salt bridge locks the peptide into a stable alpha-helical conformation; and the C-terminal P37 residue makes contact with the extracellular receptor domain. This three-point structural engagement enables non-selective, pan-receptor activation of all four amylin and calcitonin receptor subtypes. AMY1R, AMY2R, and AMY3R are heterodimeric complexes formed by the calcitonin receptor (CTR) co-assembling with receptor activity-modifying proteins RAMP1, RAMP2, and RAMP3, respectively. All four receptor subtypes, including the unmodified CTR, are engaged by cagrilintide with comparable affinity. The downstream signal is Gs-coupled cAMP accumulation in neurons of the area postrema and nucleus tractus solitarius (NTS) - circumventricular hindbrain structures lacking a blood-brain barrier - projecting appetite-suppressive input to the hypothalamic arcuate and paraventricular nuclei through an amylin-specific circuit topology mechanistically independent of GLP-1R signalling.

Semaglutide → GLP-1 Receptor (GLP-1R - Class B GPCR): Semaglutide's 31-residue backbone carries two key modifications: an Aib8 (alpha-aminoisobutyric acid) substitution at position 8 that blocks the primary DPP-4 cleavage site, eliminating the dominant plasma inactivation mechanism; and a C18 fatty-diacid modification at Lys34 via a hydrophilic OEG (oligo-ethylene glycol) linker that enables reversible albumin binding and a plasma half-life of approximately 160 hours. Mechanistically, semaglutide docks at the GLP-1R extracellular domain, engaging the receptor via a two-step binding mechanism: initial contact at the extracellular N-terminal domain followed by deep insertion of the N-terminal alpha-helix into the transmembrane bundle. GLP-1R activation couples to Gs protein → adenylyl cyclase → intracellular cAMP elevation → PKA activation. In pancreatic β-cell model systems, PKA phosphorylates KATP channel regulatory subunits and voltage-gated calcium channels, driving glucose-dependent insulin exocytosis. In central GLP-1R-expressing neurons of the vagal afferent system and hypothalamic nuclei, the same cAMP cascade initiates appetite-suppressive signalling and gastric motility delay.

Dual-Pathway Architecture - Mechanistic Rationale for Co-Administration: The scientific rationale for studying CagriSema as a combination is mechanistic non-overlap. Amylin receptors (cagrilintide's targets) and GLP-1R (semaglutide's target) are different receptor superfamilies, couple to Gs via distinct molecular interfaces, activate partly overlapping but not identical intracellular signalling networks, and project through different primary neural circuits in the brainstem. Amylin receptor signalling from the area postrema reaches hypothalamic feeding centres via the NTS relay. GLP-1R signalling from vagal afferents reaches the hypothalamic arcuate nucleus via a partially distinct anatomical route. Investigational co-administration data (Enebo et al. 2021, Lancet, PMID 33894838) documented additive pharmacodynamic output beyond either agent's monotherapy profile - a finding consistent with receptor system complementarity rather than pathway redundancy, and the mechanistic basis for this compound class as a dual-receptor research tool.

What are the Potential Research Applications of Cagrilintide + Semaglutide?

CS5 - Standard Assay and Pilot Research

• Amylin/GLP-1R dual receptor binding studies: CS5 (5mg) provides sufficient material for competitive radioligand displacement assays at 4–6 concentration points in AMY1R-expressing and GLP-1R-expressing cell lines, characterising binding kinetics for each peptide within the same experimental system
• cAMP signalling pathway investigation: Gs-coupled cAMP accumulation assays (HTRF, AlphaScreen) in amylin receptor- or GLP-1R-transfected HEK-293 cells to characterise Gs-coupling efficiency and receptor activation thresholds for each peptide independently and in combination
• Plasma protein binding competition research: Both peptides' albumin-binding modifications (α-C16 fatty-diacid for cagrilintide; C18-OEG for semaglutide) produce potential binding competition at serum albumin. CS5 volume supports in vitro albumin displacement and half-life modelling research
• Pilot and method development: Single-vial CS5 format is appropriate for assay calibration, method development, and preliminary receptor pharmacology work before committing to the multi-vial CS10 or CS20 kit formats

CS10 - Extended Pharmacology and Multi-Month Protocols

• Full dose-response pharmacology: 100mg total across 10 matched vials enables construction of complete sigmoidal concentration-response curves (8–10 points from pM to μM) for cAMP accumulation, receptor binding, and β-arrestin recruitment assays within a single matched-batch research programme
• Longitudinal amylin/GLP-1 dual pathway dynamics: 10-vial kit supports 3–6-month IACUC-compliant animal model studies with consistent once-weekly research reagent supply from a single matched lot, enabling investigation of receptor adaptation, pharmacodynamic tolerance, and washout kinetics over extended time courses
• Comparative amylin DACRA pharmacology: Sufficient material to run CagriSema dual-receptor blend vs cagrilintide monotherapy vs semaglutide monotherapy across multiple concentration points and time points in matched assay conditions - isolating the mechanistic contribution of each receptor system

CS20 - Large-Scale and Multi-Site Research

• 6–12-month longitudinal animal model protocols: 200mg total (10 × 20mg vials) from a single matched lot provides the maximum research reagent volume for extended IACUC-compliant longitudinal studies covering full treatment and washout periods
• Comprehensive multi-concentration pharmacology: Sufficient material for 10+ concentration point dose-response characterisation, receptor binding Bmax/Kd determination, and receptor desensitisation/resensitisation kinetics in parallel assay arms
• Multi-site parallel study replication: Large matched-lot supply enables simultaneous research across independent laboratory sites from a single batch, eliminating inter-lot variability as an experimental confound in multi-site study designs

What are the Potential Side Effects of Cagrilintide + Semaglutide?

• Gastrointestinal pathway signals are the most consistently documented pharmacodynamic adverse signals for GLP-1R agonists in investigational models; nausea and gastric motility perturbation are mechanistically expected from vagal GLP-1R activation and should be accounted for as off-target pathway interactions in biological research systems where gastrointestinal endpoints are measured
• Amylin receptor engagement in the area postrema - a circumventricular region sensitive to emetic stimuli - has been associated with nausea signals in cagrilintide monotherapy investigational data (Lau et al. 2021, Lancet, PMID 34798060); researchers should account for area postrema amylin receptor activation in any study design with emesis or gastrointestinal motility as a measured endpoint
• No controlled toxicological data have been established specifically for this co-formulated dual-peptide research blend. All adverse signal references are extrapolated from individual peptide investigational studies conducted under clinical or preclinical research conditions
• No human safety data has been established for this specific research blend formulation at any of the three kit concentrations. Data remains limited and findings are not consistent across all model systems

Risk & Handling

Handling Precautions

• Trained laboratory personnel only in a controlled laboratory environment
• PPE: nitrile gloves, laboratory coat, and eye protection required at minimum
• Reconstitute each vial under aseptic conditions with bacteriostatic water; do not pool vials across the kit unless the experimental design specifically requires combined reconstitution
• Avoid aerosol generation during lyophilized powder reconstitution; both peptides are physiologically active at neuroendocrine receptor systems

Exposure Risks

• Risk Tier: MODERATE - both cagrilintide and semaglutide are physiologically active at amylin/calcitonin receptors and GLP-1R, respectively. Unintended biological exposure may activate appetite-regulatory, insulin secretion, and gastrointestinal motility pathways in biological systems. No human safety data has been established for this dual-peptide research blend at any kit size. The CS20 format (20mg/vial) carries elevated handling caution requirements relative to CS5 due to the higher per-vial peptide mass. No chronic toxicity data exists for either peptide at research-grade injectable concentrations. Dependency or abuse potential has not been characterised for either compound

Storage

• Store all lyophilized vials (CS5, CS10, CS20) at −20°C in sealed, light-protected containers throughout the research programme
• Reconstitute individual vials with bacteriostatic water under aseptic conditions as required for each experimental session; do not refreeze reconstituted peptide solution
• Stable for ≥24 months under recommended lyophilized storage conditions; reconstituted stability is formulation-dependent and should be confirmed for specific buffer and temperature conditions

FAQs

How do the three kit formats differ, and which is appropriate for a given research programme?

CS5 (5mg/vial, single vial) is calibrated for standard receptor assay work, assay development, and pilot studies. CS10 (10mg/vial, 100mg total, 10-vial kit) is designed for full dose-response pharmacology, multi-arm parallel experimental designs, and 3–6-month longitudinal animal model protocols. CS20 (20mg/vial, 200mg total, 10-vial kit) provides maximum reagent volume for 6–12-month longitudinal studies, comprehensive 10+ point dose-response characterisation, or multi-site parallel replication from a single matched lot. The mechanism and compound ratio are identical across all three.

What distinguishes cagrilintide from earlier amylin analogs such as pramlintide in receptor pharmacology research?

Pramlintide (Symlin®) is a human amylin analogue with moderate amylin receptor affinity and a plasma half-life of approximately 48 minutes, requiring multiple daily administrations. Cagrilintide, by contrast, is engineered with a C16 fatty-diacid albumin-binding modification producing ~159–195-hour half-life and is classified as a DACRA - it activates all four amylin/calcitonin receptor subtypes (AMY1R, AMY2R, AMY3R, CTR) with a 'bypass' binding mode resolved by cryo-EM that is structurally distinct from pramlintide's receptor engagement geometry. In receptor pharmacology research, cagrilintide's extended half-life and pan-receptor profile make it a different class of research tool from pramlintide despite shared receptor family membership.

What are the documented pharmacokinetic half-lives for each peptide?

Cagrilintide: approximately 159–195 hours in published investigational pharmacokinetic data (Enebo et al. 2021, Lancet, PMID 33894838). Semaglutide: approximately 160 hours in published clinical pharmacokinetic data. Both half-lives are achieved through distinct fatty-acid/albumin-binding mechanisms and support once-weekly dosing interval designs in IACUC-compliant animal model research protocols.

Why does the CS20 kit format carry higher handling caution requirements?

The CS20 format provides 20mg of peptide per vial (10mg cagrilintide + 10mg semaglutide). Higher per-vial peptide mass increases the potential for biologically meaningful exposure in the event of handling errors compared with CS5 (5mg/vial) or CS10 (10mg/vial). Both peptides are neuroendocrine receptor active - cagrilintide at amylin/calcitonin receptors and semaglutide at GLP-1R. No human safety data has been established for either peptide at research-grade injectable concentrations, making any unintended exposure a risk of indeterminate consequence.

Is the semaglutide in this kit the same compound as Ozempic or Wegovy?

Semaglutide as a chemical entity shares the amino acid sequence and fatty-acid modification of pharmaceutical semaglutide products. However, this research kit is a lyophilized research reagent formulation - not a pharmaceutical drug product formulated with approved excipients, preservatives, or sterile delivery devices. Ozempic® and Wegovy® are FDA-approved prescription drugs available only through licensed healthcare providers. RCDbio does not supply pharmaceutical-grade semaglutide.

Note: semaglutide is separately FDA-approved as a prescription drug under the brand names Ozempic® (type 2 diabetes), Wegovy® (obesity), and Rybelsus® (oral, type 2 diabetes). This research kit is not that product and is not sold for therapeutic use.

What storage conditions are required for all three kit formats?

Store lyophilized vials at −20°C in sealed, light-protected containers. Reconstitute with bacteriostatic water under aseptic conditions as needed per experimental session. Do not refreeze reconstituted solution. Stable ≥24 months, lyophilized under recommended conditions across all three kit formats (CS5, CS10, CS20).

References

• Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet. 2021;398(10317):2160–2172. https://pubmed.ncbi.nlm.nih.gov/34798060/
• Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. The Lancet. 2021;397(10286):1736–1748. https://pubmed.ncbi.nlm.nih.gov/33894838/

Disclaimer: Cagrilintide + Semaglutide (CagriSema) is exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, prevent, treat, or cure any disease or medical condition.

The Food and Drug Administration has not evaluated the statements on our website. This product is not approved for human or veterinary use. Researchers must comply with all applicable local, state, and federal laws and regulations governing the purchase and use of research compounds. By purchasing, you agree to our Terms and Conditions. RCDbio reserves the right to refuse sales to unauthorized individuals.

ATTENTION: All RCDbio products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not intended for human consumption, veterinary use, or any other non-research application. For queries, complaints, or support, contact support@rcdbio.co